DRAINAD
LIVE

Serial Number

79206144

Owner

Immungenetics AG

Filing Date

Sep 30, 2016

Add to watchlist:

No watchlists yet
View on USPTO

DRAINAD Trademark

Serial Number: 79206144 • Registration: 5409575

DRAINAD is a trademark filed by Immungenetics AG on September 30, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Immungenetics AG (3 trademarks)

Eifflerstr. 43

Entity Type: 25

Trademark Details

Filing Date

September 30, 2016

Registration Date

February 27, 2018

Published for Opposition

December 12, 2017

Cancellation Date

September 13, 2024

Goods & Services

Biochemical and chemical preparations for medical purposes in particular those with the active ingredient thiethylperazine, for use in neurodegenerative diseases; biochemical and chemical preparations for medical purposes in particular those with the active ingredient thiethylperazine, for use in dementia disorders and their earlier stages, in particular for use in Alzheimer's disease and mild cognitive impairment; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for prevention against neurodegenerative diseases; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for preventing dementia disorders and their earlier stages, in particular for preventing Alzheimer's disease and mild cognitive impairment; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for the treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes in oral administration forms, namely, pills, tablets, dragées, capsules, liquids, drops, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes in oral administration form, namely, pills, tablets, dragées, capsules, liquids, drops, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of Alzheimer's disease and mild cognitive impairment; biochemical and chemical preparations for medical purposes, in particular those with the active ingredient thiethylperazine, for the treatment of dementia disorders and their earlier stages, in particular for the treatment of Alzheimer's disease and mild cognitive impairment; biochemical and chemical preparations for medical purposes in parenteral administration form, namely, injection solutions and infusion solutions, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of neurodegenerative diseases; biochemical and chemical preparations for medical purposes in parenteral administration forms, namely, injection solutions and infusion solutions, in particular including as active ingredient thiethylperazine, for the prevention and/or treatment of Alzheimer's disease and mild cognitive impairment

Chemical products for the production of viral, retroviral and non-viral vectors

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Sep 27, 2025 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 5, 2025 INTS
INVALIDATION PROCESSED
Sep 5, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
May 13, 2025 INTR
CANCELLED SECTION 71
Sep 13, 2024 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 27, 2023 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 11, 2022 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Oct 20, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jul 26, 2019 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 29, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 4, 2018 FICS
FINAL DISPOSITION PROCESSED
Jun 4, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 27, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 27, 2018 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 21, 2018 TCCA
PUBLISHED FOR OPPOSITION
Dec 12, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Dec 8, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 22, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 22, 2017 OP2R
NOTICE OF PUBLICATION
Nov 22, 2017 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 3, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2017 CRFA
ASSIGNED TO LIE
Oct 12, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 29, 2017 TROA
REFUSAL PROCESSED BY IB
Jun 3, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 18, 2017 RFCS
REFUSAL PROCESSED BY MPU
May 18, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 10, 2017 RFCR
NON-FINAL ACTION WRITTEN
May 9, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
May 6, 2017 MAFR
ASSIGNED TO EXAMINER
May 2, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 2, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 27, 2017 REPR